시장보고서
상품코드
1322229

세계의 DNA 치료제 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

DNA Repair Drugs Market (Drug Type: PARP Inhibitors, Alkylating Agents, and Others; and Dosage Form: Tablets, Capsules, and Injectable) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 160 Pages | 배송안내 : 2-10일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

DNA 치료제 시장-보고서 범위

세계의 DNA 치료제(DNA Repair Drugs) 시장에 대한 TMR 보고서는 과거 및 현재의 성장 동향과 2023년에서 2031년까지 예측 기간 동안 시장 지표의 귀중한 통찰력을 얻을 수 있는 기회를 연구하고 있습니다. 2023년을 기준년도로, 2031년을 예측년도로 설정하여, 2017년부터 2031년까지 세계의 시장 매출 정보를 제공합니다. 또한 2023년부터 2031년까지 세계의 시장 CAGR(%)도 제공합니다.

보고서는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 조사 활동의 대부분이 이루어졌으며 분석가들은 주요 오피니언 리더, 산업 리더, 오피니언 제조사와 인터뷰를 실시했습니다. 2차 조사는 DNA 치료제 시장을 이해하기 위해 주요 기업의 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서 참조를 포함합니다.

세계의 DNA 치료제 시장 경쟁 상황을 자세히 파악하고 있습니다. 세계의 DNA 치료제 시장에서 활동하는 주요 플레이어가 확인되었으며, 이들 각각은 다양한 속성 관점에서 프로파일링됩니다. 기업 개요, 재무 상황, 최근 동향, SWOT는 이 보고서에 소개 된 세계의 DNA 치료제 시장 플레이어 속성입니다.

목차

제1장 서문

제2장 전제 조건 및 연구 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

  • 소개
  • 개요
  • 시장 역학
  • 전 세계 시장 분석 및 예측(2017-2031년)

제5장 중요한 통찰

  • 기술의 진보
  • 주요 국가별 질병 유병률 및 이환율
  • 파이프라인 분석
  • 지역/세계별 규제 시나리오
  • COVID-19 팬데믹의 산업에 대한 영향(밸류체인 및 단기·중기·장기적인 영향)

제6장 시장 분석 및 예측 : 의약품 유형별

  • 소개 및 정의
  • 주요 조사 결과/발전
  • 시장 금액 예측 : 의약품 유형별(2017-2031년)
    • PARP 억제제
    • 알킬화제
    • 기타
  • 시장 매력 분석 : 의약품 유형별

제7장 시장 분석 및 예측 : 질환별

  • 소개 및 정의
  • 주요 조사 결과/발전
  • 시장 금액 예측 : 질환별(2017-2031년)
    • 유방암
    • 난소암
    • 폐암
    • 두경부암
    • 기타
  • 시장 매력 분석 : 질환별

제8장 시장 분석 및 예측 : 제형별

  • 소개 및 정의
  • 주요 조사 결과/발전
  • 시장 금액 예측 : 제형별(2017-2031년)
    • 정제
    • 캡슐
    • 주사제
  • 시장 매력 분석 : 제형별

제9장 시장 분석 및 예측 : 유통 채널별

  • 소개 및 정의
  • 주요 조사 결과/발전
  • 시장 금액 예측 : 유통 채널별(2017-2031년)
    • 소매 약국
    • 병원 약국
    • 온라인 약국
  • 시장 매력도 분석 : 유통 채널별

제10장 시장 분석 및 예측 : 지역별

  • 주요 조사 결과
  • 시장 금액 예측 : 지역별(2017-2031년)
    • 북미
    • 유럽
    • 아시아 태평양 지역
    • 남미
    • 중동 및 아프리카
  • 국가·지역별 시장 매력도

제11장 북미 시장 분석 및 예측

제12장 유럽 시장 분석 및 예측

제13장 아시아 태평양 시장 분석 및 예측

제14장 남미 시장 분석 및 예측

제15장 중동 및 아프리카 시장 분석 및 예측

제16장 경쟁 상황

  • 시장 기업-경쟁 매트릭스(기업의 계층 및 규모별)
  • 시장 점유율 분석 : 기업별(2021년)
  • 기업 개요
    • AstraZeneca plc
    • Clovis Oncology
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Merck &Co. Inc.
    • Novartis AG
    • Johnson &Johnson
    • Bristol Myers Squibb Company
    • Onxeo
LYJ 23.10.10

DNA Repair Drugs Market - Scope of Report

TMR's report on the global DNA Repair Drugs Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global DNA Repair Drugs Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global DNA Repair Drugs Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the DNA Repair Drugs Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global DNA Repair Drugs Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global DNA Repair Drugs Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global DNA Repair Drugs Market.

The report delves into the competitive landscape of the global DNA Repair Drugs Market. Key players operating in the global DNA Repair Drugs Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global DNA Repair Drugs Market profiled in this report.

Key Questions Answered in Global DNA Repair Drugs Market Report:

  • What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
  • What are the opportunities in the global DNA Repair Drugs Market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

DNA Repair Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global DNA Repair Drugs Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global DNA Repair Drugs Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global DNA Repair Drugs.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global DNA Repair Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global DNA Repair Drugs Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
  • 5.3. Pipeline Analysis
  • 5.4. Regulatory Scenario by Region/Globally
  • 5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global DNA Repair Drugs Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Type, 2017-2031
    • 6.3.1. PARP Inhibitors
    • 6.3.2. Alkylating Agents
    • 6.3.3. Others
  • 6.4. Market Attractiveness Analysis, by Drug Type

7. Global DNA Repair Drugs Market Analysis and Forecast, by Dosage Form

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Dosage Form, 2017-2031
    • 7.3.1. Breast Cancer
    • 7.3.2. Ovarian Cancer
    • 7.3.3. Lung Cancer
    • 7.3.4. Head and Neck Cancer
    • 7.3.5. Others
  • 7.4. Market Attractiveness Analysis, by Dosage Form

8. Global DNA Repair Drugs Market Analysis and Forecast, by Dosage Form

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Dosage Form, 2017-2031
    • 8.3.1. Tablets
    • 8.3.2. Capsules
    • 8.3.3. Injectables
  • 8.4. Market Attractiveness Analysis, by Dosage Form

9. Global DNA Repair Drugs Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Retail Pharmacies
    • 9.3.2. Hospital Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness Analysis, by Distribution Channel

10. Global DNA Repair Drugs Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2017-2031
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Country/Region

11. North America DNA Repair Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Type, 2017-2031
    • 11.2.1. PARP Inhibitors
    • 11.2.2. Alkylating Agents
    • 11.2.3. Others
  • 11.3. Market Value Forecast, by Dosage Form, 2017-2031
    • 11.3.1. Breast Cancer
    • 11.3.2. Ovarian Cancer
    • 11.3.3. Lung Cancer
    • 11.3.4. Head and Neck Cancer
    • 11.3.5. Others
  • 11.4. Market Value Forecast, by Dosage Form, 2017-2031
    • 11.4.1. Tablets
    • 11.4.2. Capsules
    • 11.4.3. Injectables
  • 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.5.1. Retail Pharmacies
    • 11.5.2. Hospital Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Type
    • 11.7.2. By Dosage Form
    • 11.7.3. By Dosage Form
    • 11.7.4. By Distribution Channel
    • 11.7.5. By Country/Sub-region

12. Europe DNA Repair Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Type, 2017-2031
    • 12.2.1. PARP Inhibitors
    • 12.2.2. Alkylating Agents
    • 12.2.3. Others
  • 12.3. Market Value Forecast, by Dosage Form, 2017-2031
    • 12.3.1. Breast Cancer
    • 12.3.2. Ovarian Cancer
    • 12.3.3. Lung Cancer
    • 12.3.4. Head and Neck Cancer
    • 12.3.5. Others
  • 12.4. Market Value Forecast, by Dosage Form, 2017-2031
    • 12.4.1. Tablets
    • 12.4.2. Capsules
    • 12.4.3. Injectables
  • 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.5.1. Retail Pharmacies
    • 12.5.2. Hospital Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Type
    • 12.7.2. By Dosage Form
    • 12.7.3. By Dosage Form
    • 12.7.4. By Distribution Channel
    • 12.7.5. By Country/Sub-region

13. Asia Pacific DNA Repair Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Type, 2017-2031
    • 13.2.1. PARP Inhibitors
    • 13.2.2. Alkylating Agents
    • 13.2.3. Others
  • 13.3. Market Value Forecast, by Dosage Form, 2017-2031
    • 13.3.1. Breast Cancer
    • 13.3.2. Ovarian Cancer
    • 13.3.3. Lung Cancer
    • 13.3.4. Head and Neck Cancer
    • 13.3.5. Others
  • 13.4. Market Value Forecast, by Dosage Form, 2017-2031
    • 13.4.1. Tablets
    • 13.4.2. Capsules
    • 13.4.3. Injectables
  • 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.5.1. Retail Pharmacies
    • 13.5.2. Hospital Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Type
    • 13.7.2. By Dosage Form
    • 13.7.3. By Dosage Form
    • 13.7.4. By Distribution Channel
    • 13.7.5. By Country/Sub-region

14. Latin America DNA Repair Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Type, 2017-2031
    • 14.2.1. PARP Inhibitors
    • 14.2.2. Alkylating Agents
    • 14.2.3. Others
  • 14.3. Market Value Forecast, by Dosage Form, 2017-2031
    • 14.3.1. Breast Cancer
    • 14.3.2. Ovarian Cancer
    • 14.3.3. Lung Cancer
    • 14.3.4. Head and Neck Cancer
    • 14.3.5. Others
  • 14.4. Market Value Forecast, by Dosage Form, 2017-2031
    • 14.4.1. Tablets
    • 14.4.2. Capsules
    • 14.4.3. Injectables
  • 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.5.1. Retail Pharmacies
    • 14.5.2. Hospital Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Type
    • 14.7.2. By Dosage Form
    • 14.7.3. By Dosage Form
    • 14.7.4. By Distribution Channel
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa DNA Repair Drugs Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Drug Type, 2017-2031
    • 15.2.1. PARP Inhibitors
    • 15.2.2. Alkylating Agents
    • 15.2.3. Others
  • 15.3. Market Value Forecast, by Dosage Form, 2017-2031
    • 15.3.1. Breast Cancer
    • 15.3.2. Ovarian Cancer
    • 15.3.3. Lung Cancer
    • 15.3.4. Head and Neck Cancer
    • 15.3.5. Others
  • 15.4. Market Value Forecast, by Dosage Form, 2017-2031
    • 15.4.1. Tablets
    • 15.4.2. Capsules
    • 15.4.3. Injectables
  • 15.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 15.5.1. Retail Pharmacies
    • 15.5.2. Hospital Pharmacies
    • 15.5.3. Online Pharmacies
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Drug Type
    • 15.7.2. By Dosage Form
    • 15.7.3. By Application
    • 15.7.4. By Distribution Channel
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2021)
  • 16.3. Company Profiles
    • 16.3.1. AstraZeneca plc
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Clovis Oncology
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. GlaxoSmithKline plc
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Pfizer Inc.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Merck & Co. Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Novartis AG
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Johnson & Johnson
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Bristol Myers Squibb Company
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Onxeo
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제